Bullous Pemphigoid Associated with Dipeptidyl Peptidase 4 Inhibitors for the Treatment of Type 2 Diabetes: A Multicenter Study in Istanbul

Overview

Journal Sisli Etfal Hastan Tıp Bul

Specialty General Medicine

Date 2022 Oct 28

PMID 36304224

Authors

Ece Ugurer

Ezgi Ozkur

Ilknur Kivanc Altunay

Esra Cil Sen

Ayse Esra Koku Aksu

Ilknur Ozcan

Yuksel Altuntas

Mehmet Salih Gurel

Affiliations

Soon will be listed here.

Abstract

Objectives: Recent studies have revealed an association between dipeptidyl peptidase 4 inhibitors (DPP4i) and development of bullous pemphigoid (BP). The main aim of our study is to evaluate the association between DPP4i treatment and BP development. The secondary endpoints were to evaluate clinical characteristics and biochemical parameters of the DPP4i associated BP cases and determine the differences of DPP4i associated BP disease than non-DPP4i associated BP cases.

Methods: We designed a retrospective case-control study, comparing type 2 diabetic 58 BP cases to 75 type 2 diabetic controls. Data were collected from three dermatological departments in Istanbul/Turkey, from November 1, 2008, to January 1, 2019. Medical records of each patient's demographic, clinical characteristics, drugs used, and laboratory data were reviewed.

Results: There was no statistical difference in age and gender between the patient and control group. The most common prescribed oral antidiabetic for both groups was metformin. The most commonly prescribed DPP4i was vildagliptin. Fourteen (24.1%) out of 58 diabetic patients with BP were using vildagliptin, 12 (20.7%) out of 58 diabetic BP patients were using linagliptin, 6 (10.3%) out of 58 diabetic BP patients were using sitagliptin, and 1 (1.7%) out of 58 diabetic BP patients were using saxagliptin. There was no significant difference between the two groups regarding the DPP4 is use (using DPPi at the time of diagnosis and not). Both groups had similar clinical characteristics, localizations, disease severity, comorbidities, treatment responses, and biochemical parameters. BP patients using DPP4i had statistically less mucosal involvement than BP patients not using DPP4i (p=0.044).

Conclusion: Even though there was no difference between two groups, when BP develops in diabetic patients, DPP4 is should be questioned and with cooperation with clinician's consideration of change may be planned.

References

Skandalis K, Spirova M, Gaitanis G, Tsartsarakis A, Bassukas I . Drug-induced bullous pemphigoid in diabetes mellitus patients receiving dipeptidyl peptidase-IV inhibitors plus metformin. J Eur Acad Dermatol Venereol. 2011; 26(2):249-53. DOI: 10.1111/j.1468-3083.2011.04062.x. View

Keseroglu H, Tas-Aygar G, Gonul M, Gokoz O, Ersoy-Evans S . A case of bullous pemphigoid ınduced by vildagliptin. Cutan Ocul Toxicol. 2016; 36(2):201-202. DOI: 10.1080/15569527.2016.1211670. View

Eming R, Sticherling M, Hofmann S, Hunzelmann N, Kern J, Kramer H . S2k guidelines for the treatment of pemphigus vulgaris/foliaceus and bullous pemphigoid. J Dtsch Dermatol Ges. 2015; 13(8):833-44. DOI: 10.1111/ddg.12606. View

Oya K, Fujii M, Taguchi S, Nishie W, Izumi K, Shimizu H . Localized bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitor treatment. Eur J Dermatol. 2018; 28(2):250-251. DOI: 10.1684/ejd.2018.3230. View

Lee S, Lee H, Yoon M, Kim D . Association of Dipeptidyl Peptidase 4 Inhibitor Use With Risk of Bullous Pemphigoid in Patients With Diabetes. JAMA Dermatol. 2019; 155(2):172-177. PMC: 6439542. DOI: 10.1001/jamadermatol.2018.4556. View

Liu S, Chen W, Chi C . Association Between Medication Use and Bullous Pemphigoid: A Systematic Review and Meta-analysis. JAMA Dermatol. 2020; 156(8):891-900. PMC: 7301306. DOI: 10.1001/jamadermatol.2020.1587. View

Hofmann S, Voith U, Schonau V, Sorokin L, Bruckner-Tuderman L, Franzke C . Plasmin plays a role in the in vitro generation of the linear IgA dermatosis antigen LADB97. J Invest Dermatol. 2009; 129(7):1730-9. DOI: 10.1038/jid.2008.424. View

Deacon C, Lebovitz H . Comparative review of dipeptidyl peptidase-4 inhibitors and sulphonylureas. Diabetes Obes Metab. 2015; 18(4):333-47. DOI: 10.1111/dom.12610. View

Thornberry N, Gallwitz B . Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4). Best Pract Res Clin Endocrinol Metab. 2009; 23(4):479-86. DOI: 10.1016/j.beem.2009.03.004. View

10.

Gonzalez-Gronow M, Kaczowka S, Gawdi G, Pizzo S . Dipeptidyl peptidase IV (DPP IV/CD26) is a cell-surface plasminogen receptor. Front Biosci. 2007; 13:1610-8. DOI: 10.2741/2785. View

11.

Muscelli E, Casolaro A, Gastaldelli A, Mari A, Seghieri G, Astiarraga B . Mechanisms for the antihyperglycemic effect of sitagliptin in patients with type 2 diabetes. J Clin Endocrinol Metab. 2012; 97(8):2818-26. DOI: 10.1210/jc.2012-1205. View

12.

Plaquevent M, Tetart F, Fardet L, Ingen-Housz-Oro S, Valeyrie-Allanore L, Bernard P . Higher Frequency of Dipeptidyl Peptidase-4 Inhibitor Intake in Bullous Pemphigoid Patients than in the French General Population. J Invest Dermatol. 2018; 139(4):835-841. DOI: 10.1016/j.jid.2018.10.045. View

13.

Benzaquen M, Borradori L, Berbis P, Cazzaniga S, Valero R, Richard M . Dipeptidyl peptidase IV inhibitors, a risk factor for bullous pemphigoid: Retrospective multicenter case-control study from France and Switzerland. J Am Acad Dermatol. 2017; 78(6):1090-1096. DOI: 10.1016/j.jaad.2017.12.038. View

14.

Kasperkiewicz M, Zillikens D . The pathophysiology of bullous pemphigoid. Clin Rev Allergy Immunol. 2007; 33(1-2):67-77. DOI: 10.1007/s12016-007-0030-y. View

15.

Kridin K, Bergman R . Association of Bullous Pemphigoid With Dipeptidyl-Peptidase 4 Inhibitors in Patients With Diabetes: Estimating the Risk of the New Agents and Characterizing the Patients. JAMA Dermatol. 2018; 154(10):1152-1158. PMC: 6233738. DOI: 10.1001/jamadermatol.2018.2352. View

16.

Garcia-Diez I, Ivars-Lleo M, Lopez-Aventin D, Ishii N, Hashimoto T, Iranzo P . Bullous pemphigoid induced by dipeptidyl peptidase-4 inhibitors. Eight cases with clinical and immunological characterization. Int J Dermatol. 2018; 57(7):810-816. DOI: 10.1111/ijd.14005. View

17.

Chijiwa C, Takeoka S, Kamata M, Tateishi M, Fukaya S, Hayashi K . Decrease in eosinophils infiltrating into the skin of patients with dipeptidyl peptidase-4 inhibitor-related bullous pemphigoid. J Dermatol. 2018; 45(5):596-599. DOI: 10.1111/1346-8138.14245. View

18.

Amber K, Murrell D, Schmidt E, Joly P, Borradori L . Autoimmune Subepidermal Bullous Diseases of the Skin and Mucosae: Clinical Features, Diagnosis, and Management. Clin Rev Allergy Immunol. 2017; 54(1):26-51. DOI: 10.1007/s12016-017-8633-4. View

19.

Ildefonso Mendonca F, Martin-Gutierrez F, Rios-Martin J, Camacho-Martinez F . Three Cases of Bullous Pemphigoid Associated with Dipeptidyl Peptidase-4 Inhibitors - One due to Linagliptin. Dermatology. 2016; 232(2):249-53. DOI: 10.1159/000443330. View

20.

Bene J, Moulis G, Bennani I, Auffret M, Coupe P, Babai S . Bullous pemphigoid and dipeptidyl peptidase IV inhibitors: a case-noncase study in the French Pharmacovigilance Database. Br J Dermatol. 2016; 175(2):296-301. DOI: 10.1111/bjd.14601. View